AI Could Drive 60% of New Drugs Within 10 Years as Pharma Targets 12-18 Month Discovery
Updated
Updated · Financial Times · Jun 30
AI Could Drive 60% of New Drugs Within 10 Years as Pharma Targets 12-18 Month Discovery
3 articles · Updated · Financial Times · Jun 30
Summary
Capgemini estimates AI-driven platforms could generate about 60% of new molecular entities within a decade, up from roughly 12% of drug pipelines today.
AlphaFold2's 2021 breakthrough in predicting protein structures helped accelerate AI use in target identification, molecule design and analysis of protein interactions once too complex to model accurately.
Drugmakers expect the first payoff in speed: early discovery work that now takes four to five years could shrink to 12-18 months, while lab and clinical-trial recruitment costs also fall.
The technology may also improve the industry's poor hit rate—only 1 in 10 drugs entering clinical trials wins approval—by designing safer, better-targeted molecules and enabling more personalized treatments.
A fully AI-developed medicine is still years away because biology and human testing cannot be compressed, meaning today's clinical results largely reflect AI tools from five to 10 years ago.
As AI accelerates drug creation, will the cures it discovers be affordable for the average person or only for the wealthy?
With AI poised to replace animal trials, how will regulators verify the safety of drugs designed entirely within a computer?
AI-Discovered Drugs Achieve 90% Phase I Success: Transforming Pharma R&D, Investment, and Regulation in 2026
Overview
Artificial intelligence is rapidly transforming pharmaceutical research and development, as seen by major clinical milestones for AI-discovered drugs in 2026. AI-designed drug candidates now achieve a 90% success rate in Phase I safety trials, a significant improvement over traditional small molecules that often failed due to toxicity or poor bioavailability. This leap is made possible by advanced generative adversarial networks and deep learning, which optimize both binding affinity and safety before any physical synthesis. These breakthroughs mark a shift from trial-and-error to precise engineering in drug development, promising safer and more efficient therapies.